With new indications set to roll out for mega-blockbuster Cosentyx, Marie-France Tschudin, president of Novartis AG's innovative medicines international operations and chief commercial officer, has outlined the company's lifecycle management plans and the importance the Swiss major is placing on immunology to Scrip.
Novartis Committed To Carving Out More Indications For Cosentyx
Close To EU Approval For Hidradenitis Suppurativa
The Swiss behemoth’s chief commercial officer Marie-France Tschudin tells Scrip that the firm will keep expanding Cosentyx into disease areas “that have been a little bit neglected.”
More from Immunological
More from Therapy Areas
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.